KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Supernus Pharmaceuticals (SUPN) Interest & Investment Income: 2010-2018

Historic Interest & Investment Income for Supernus Pharmaceuticals (SUPN) over the last 9 years, with Dec 2018 value amounting to $13.8 million.

  • Supernus Pharmaceuticals' Interest & Investment Income fell 41.32% to $3.3 million in Q3 2020 from the same period last year, while for Sep 2020 it was $19.8 million, marking a year-over-year decrease of 1.76%. This contributed to the annual value of $13.8 million for FY2018, which is 383.34% up from last year.
  • According to the latest figures from FY2018, Supernus Pharmaceuticals' Interest & Investment Income is $13.8 million, which was up 383.34% from $2.9 million recorded in FY2017.
  • In the past 5 years, Supernus Pharmaceuticals' Interest & Investment Income registered a high of $13.8 million during FY2018, and its lowest value of $348,000 during FY2014.
  • For the 3-year period, Supernus Pharmaceuticals' Interest & Investment Income averaged around $6.1 million, with its median value being $2.9 million (2017).
  • Data for Supernus Pharmaceuticals' Interest & Investment Income shows a peak YoY spiked of 383.34% (in 2018) over the last 5 years.
  • Over the past 5 years, Supernus Pharmaceuticals' Interest & Investment Income (Yearly) stood at $348,000 in 2014, then skyrocketed by 95.69% to $681,000 in 2015, then soared by 115.42% to $1.5 million in 2016, then skyrocketed by 95.23% to $2.9 million in 2017, then surged by 383.34% to $13.8 million in 2018.